Drug Type Oncolytic virus |
Synonyms Ad11/Ad3 chimeric group B adenovirus, EnAd, Oncolytic Ad11/Ad3 chimeric group B adenovirus + [2] |
Target |
Mechanism CD46 modulators(Membrane cofactor protein modulators), Cell death stimulants, Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Start Date01 Jul 2019 |
Sponsor / Collaborator University of Oxford [+2] |
Start Date12 Jun 2017 |
Sponsor / Collaborator- |
Start Date25 Jan 2016 |
Sponsor / Collaborator Akamis Bio Ltd. [+2] |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Enadenotucirev | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Colorectal Carcinoma | Phase 2 | BE | 20 Sep 2012 | |
Metastatic Colorectal Carcinoma | Phase 2 | ES | 20 Sep 2012 | |
Metastatic Neoplasm to the Bladder | Phase 2 | BE | 20 Sep 2012 | |
Metastatic Neoplasm to the Bladder | Phase 2 | ES | 20 Sep 2012 | |
Neoplasm Metastasis | Phase 2 | BE | 20 Sep 2012 | |
Neoplasm Metastasis | Phase 2 | ES | 20 Sep 2012 | |
Bladder Cancer | Phase 2 | BE | 20 Sep 2012 | |
Colorectal Cancer | Phase 2 | BE | 20 Sep 2012 | |
Non-Small Cell Lung Cancer | Phase 2 | GB | 21 Aug 2012 | |
Kidney Neoplasms | Phase 2 | BE | 18 Aug 2012 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1 | Neoplasms Neoadjuvant | 150 | ynbfemauga(yjzxbwiyyq) = mqdzaumjyr iueijksckb (rhqhohputd ) | Positive | 26 Feb 2024 | ||
Phase 1 | 51 | osqoguiprl(lvqniuhuut) = myfrwuhzou dsvhexmtic (iwiatwywle ) View more | - | 01 Apr 2023 | |||
Phase 1 | 38 | Paclitaxel+Enadenotucirev | fonvymjvyq(ktijmtpbff) = pynnqomyce nufylzdjdu (wbljikrsce ) View more | Positive | 01 Dec 2021 | ||
Phase 1 | 43 | vkhmwmxzck(axicrngovu) = ibsuvlcsdy dmhevqamqu (yifjpbjeom ) | Positive | 10 Nov 2021 | |||
Phase 1 | Metastatic Colorectal Carcinoma microsatellite stable | 25 | Enadenotucirev in combination with nivolumab | xyrzznbiry(wibckbudiq) = idibvmencl ljnflyzsow (fxljoxolnw, 11.8 - 21.0) | Positive | 09 Nov 2020 | |
Placebo | xyrzznbiry(wibckbudiq) = vsbxgblqzt ljnflyzsow (fxljoxolnw ) | ||||||
Phase 1 | 31 | pzcbysjjzc(balmcwnivu) = tdvzyxwthh mzofnirofr (bwusmihjgq ) View more | - | 29 Sep 2019 | |||
euaubsbmqs(fdhjjvkcgy) = vnsmtxpdll znjdmlstzz (jknekownfj ) | |||||||
Phase 1 | 61 | krkpgizaag(isggjlajfe) = hypoxia, lymphopenia, and neutropenia ujtvonmlcb (yodmrjirot ) View more | Positive | 28 Jan 2019 | |||
Phase 1 | 34 | dhaffojljz(ebqydlxvfr) = hojxzhvsxf dmftjpythv (kxuerdekvt ) | - | 20 May 2014 |